To receive and adopt the audited consolidated financial statements and the reports of directors (the Directors) and the auditors of the Company for the year ended December 31, 2025.
To re-elect Dr. Tony Xu Han as an executive Director.
To re-elect Dr. Yan Li as an executive Director.
To re-elect Mr. Ichijo Futakawa as a non-executive Director.
To re-elect Mr. Jean-François Salles as a non-executive Director.
To re-elect Ms. Huiping Yan as an independent non-executive Director.
To re-elect Mr. David Zhang as an independent non-executive Director.
To re-elect Dr. Tony Fan-cheong Chan as an independent non-executive Director.
To authorize the board of Directors (the Board) to fix the Directors remuneration
To give a general mandate to the Directors to allot, issue or deal with additional Class A Ordinary Shares and/or to resell treasury Shares not exceeding 20% of the total number of issued Shares (excluding treasury Shares).
To give a repurchase mandate to the Directors to repurchase Class A Ordinary Shares and/or ADSs not exceeding 10% of the total number of issued Shares (excluding treasury Shares).
To extend the general mandate granted to the Directors to allot, issue or deal with additional Class A Ordinary Shares (including any sale and/or transfer of treasury Shares) and/or ADSs by the aggregate number of Class A Ordinary Shares and/or the Class A Ordinary Shares underlying ADSs repurchased by the Company.
To re-appoint KPMG and KPMG Huazhen LLP as the auditors of the Company until the conclusion of the next annual general meeting of the Company and to authorize the Directors to fix the remuneration of the auditors of the Company.